🎉 M&A multiples are live!
Check it out!

ProMIS Neurosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for ProMIS Neurosciences and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

ProMIS Neurosciences Overview

About ProMIS Neurosciences

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.


Founded

2005

HQ

United States of America
Employees

8

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$5.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

ProMIS Neurosciences Financials

ProMIS Neurosciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, ProMIS Neurosciences achieved revenue of n/a and an EBITDA of $2.9M.

ProMIS Neurosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See ProMIS Neurosciences valuation multiples based on analyst estimates

ProMIS Neurosciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$13.0M $2.9M XXX XXX XXX
EBITDA Margin -Infinity% Infinity% XXX XXX XXX
Net Profit -$18.1M -$13.2M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

ProMIS Neurosciences Stock Performance

As of April 15, 2025, ProMIS Neurosciences's stock price is $1.

ProMIS Neurosciences has current market cap of $18.8M, and EV of $5.5M.

See ProMIS Neurosciences trading valuation data

ProMIS Neurosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$5.5M $18.8M XXX XXX XXX XXX $-0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

ProMIS Neurosciences Valuation Multiples

As of April 15, 2025, ProMIS Neurosciences has market cap of $18.8M and EV of $5.5M.

ProMIS Neurosciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate ProMIS Neurosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for ProMIS Neurosciences and 10K+ public comps

ProMIS Neurosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $5.5M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.9x XXX XXX XXX
P/E 6.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ProMIS Neurosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

ProMIS Neurosciences Valuation Multiples

ProMIS Neurosciences's NTM/LTM revenue growth is n/a

ProMIS Neurosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.1M for the same period.

Over next 12 months, ProMIS Neurosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate ProMIS Neurosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for ProMIS Neurosciences and other 10K+ public comps

ProMIS Neurosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -122% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

ProMIS Neurosciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

ProMIS Neurosciences M&A and Investment Activity

ProMIS Neurosciences acquired  XXX companies to date.

Last acquisition by ProMIS Neurosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . ProMIS Neurosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by ProMIS Neurosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About ProMIS Neurosciences

When was ProMIS Neurosciences founded? ProMIS Neurosciences was founded in 2005.
Where is ProMIS Neurosciences headquartered? ProMIS Neurosciences is headquartered in United States of America.
How many employees does ProMIS Neurosciences have? As of today, ProMIS Neurosciences has 8 employees.
Who is the CEO of ProMIS Neurosciences? ProMIS Neurosciences's CEO is Mr. Neil K. Warma.
Is ProMIS Neurosciences publicy listed? Yes, ProMIS Neurosciences is a public company listed on NAS.
What is the stock symbol of ProMIS Neurosciences? ProMIS Neurosciences trades under PMN ticker.
When did ProMIS Neurosciences go public? ProMIS Neurosciences went public in 2005.
Who are competitors of ProMIS Neurosciences? Similar companies to ProMIS Neurosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of ProMIS Neurosciences? ProMIS Neurosciences's current market cap is $18.8M
Is ProMIS Neurosciences profitable? Yes, ProMIS Neurosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.